Has Julie Seibert, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,212 in general payments to Julie Seibert, MD across 682 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Julie Seibert, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Julie Seibert, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Julie Seibert, MD

Neurology · Fort Myers, FLNPI 1740253822

Payments from drug & device makers

$12,212in general payments, 2019–2025

Across 682 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
UCB, Inc.$1K
EMD Serono, Inc.$740
Biogen$675
Amgen$510
MDD US Operations, LLC$457
plus $7K from 52 others

What the payments were for

Consulting fees$1501%
Speaking & faculty fees$1051%
Food & beverage$11,95798%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	90	$1,515
UCB, Inc.	62	$1,303
EMD Serono, Inc.	29	$740
Biogen	37	$675
Amgen(2 entities)	23	$510
MDD US Operations, LLC	20	$457
Amneal Pharmaceuticals LLC	28	$433
Lundbeck LLC	26	$432
Sanofi	23	$401
Neurocrine Biosciences, Inc.	24	$384
AstraZeneca(2 entities)	16	$361
Lilly USA, LLC	23	$347
SK Life Science, Inc.	15	$322
Bristol Myers Squibb	24	$321
Sunovion Pharmaceuticals Inc.	19	$294
Biohaven Pharmaceutical Holding Company Ltd.	23	$277
Novartis	25	$272
Acorda Therapeutics, Inc	11	$268
Acadia Pharmaceuticals Inc	13	$244
Adamas Pharmaceuticals, Inc.	13	$236
Eisai Inc.	18	$226
Pfizer	14	$214
Genentech USA, Inc.	16	$206
Tanabe Pharma America, Inc.	9	$150
Akcea Therapeutics, Inc.	7	$120
Jazz Pharmaceuticals Inc.	6	$117
Sumitomo Pharma America, Inc.	7	$104
Boston Scientific	3	$100
Neurelis, Inc.	3	$86
Octapharma USA, Inc.	3	$75
Livanova USA, Inc.	3	$66
ANI Pharmaceuticals, Inc.	3	$61
Abbott	3	$58
Mallinckrodt Hospital Products Inc.	3	$57
Insightec,inc	2	$56
Avion Pharmaceuticals	2	$52
Vertical Pharmaceuticals, LLC	3	$45
Greenwich Biosciences, Inc.	2	$43
Biohaven Pharmaceuticals, Inc.	2	$39
Teva Pharmaceuticals USA, Inc.	2	$39
Merz Pharmaceuticals, LLC	2	$39
Kyowa Kirin, Inc.	2	$38
Collegium Pharmaceutical, Inc.	2	$36
Orphalan Inc	1	$35
Grifols USA, LLC	2	$35
Mallinckrodt Enterprises LLC	2	$33
Banner Life Sciences, LLC	1	$32
Medtronic(2 entities)	2	$31
TG Therapeutics, Inc.	2	$31
Johnson & Johnson	2	$29
Immedica Pharma US, Inc.	1	$28
Avanir Pharmaceuticals, Inc.	2	$26
Impel Pharmaceuticals Inc.	1	$25
Supernus Pharmaceuticals, Inc.	1	$21
Sobi, Inc	1	$19
Catalyst Pharmaceuticals, Inc.	1	$18
Philips North America LLC	1	$16
Argenx US, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TYSABRI$150
Mavenclad$112

How this compares

$12,212 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024

$45,018

Medicare patients

310

Services billed

407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Emgality PenGalcanezumab-Gnlm	15	$10,506
Levetiracetam	59	$2,621
Gabapentin	47	$2,280
Memantine Hcl	47	$1,015
Donepezil Hcl	97	$956
Oxcarbazepine	11	$916
Ropinirole Hcl	18	$847
Topiramate	39	$695
Nortriptyline Hcl	19	$590
Lamotrigine	39	$488
Baclofen	27	$426
Primidone	11	$406
Citalopram HbrCitalopram Hydrobromide	44	$201
Quetiapine Fumarate	11	$193
Carbidopa-LevodopaCarbidopa/Levodopa	13	$145

Paid to pharmacies, not to this prescriber.

Other neurology in Fort Myers

Wendy BondFort Myers$14.7M
Mark GoldsteinAtlantis$36.1M
Derrick RobertsonTampa$27.6M
Beth SafirsteinHallandale Beach$25.7M
Michael PfefferMiami$24.5M
Mark BrodyDelray Beach$20.5M
Paayal PatelWest Palm Beach$17.3M
William HoneycuttMaitland$14.1M
Julie SchwartzbardAventura$13.6M
Rekha GandhiWinter Park$13.4M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →